Question 1

What is Neurocrine Biosciences?

Accepted Answer

Neurocrine Biosciences is a Company.

Question 2

How often does Neurocrine Biosciences appear in global news?

Accepted Answer

Tracked across 5 news events drawn from 99 articles.

Question 3

When was Neurocrine Biosciences first tracked by Ergen?

Accepted Answer

First tracked on Apr 01, 2026.

Question 4

When was Neurocrine Biosciences last mentioned in news?

Accepted Answer

Last active on Aug 07, 2026.

Question 5

What is Neurocrine Biosciences's current news sentiment?

Accepted Answer

Aggregate sentiment score: 38 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Neurocrine Biosciences in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 5 events.

Question 7

What is the most recent event involving Neurocrine Biosciences?

Accepted Answer

Neurocrine Acquires Soleno for $2.9B (Apr 06, 2026, 6 articles).

Question 8

Who is Neurocrine Biosciences most connected to?

Accepted Answer

Top relationships: MiNK Therapeutics, MiNK Therapeutics.

Question 9

How did the "Neurocrine Acquires Soleno for $2.9B" event impact Neurocrine Biosciences?

Accepted Answer

Neurocrine Biosciences is acquiring MiNK Therapeutics for $2.9 billion, expanding its portfolio in endocrinology and rare diseases with the addition of VYKAT XR. This acquisition is expected to accelerate revenue growth and diversify its product offerings.

Question 10

How did the "Neurocrine Acquires Soleno for $2.9B" event impact Neurocrine Biosciences?

Accepted Answer

Neurocrine Biosciences is acquiring MiNK Therapeutics for $2.9 billion, expanding its portfolio into metabolic disorders with the addition of VYKAT XR. This deal is seen as a strategic entry into the metabolic disease market.

Question 11

How did the "Monteverde Investigates Multiple Mergers, Sales" event impact Neurocrine Biosciences?

Accepted Answer

Neurocrine Biosciences, Inc. is the proposed acquirer of MiNK Therapeutics.

Question 12

How did the "Nxera Pharma Q2 2026 Results" event impact Neurocrine Biosciences?

Accepted Answer

Neurocrine initiated a Phase 2 study of NBI-1117570 and paid Nxera US$22.5 million in milestone payments. This collaboration advances a potential schizophrenia treatment.

Question 13

How did the "Vertex acquires Crinetics for $10B" event impact Neurocrine Biosciences?

Accepted Answer

Competitor with Crenessity for CAH; sets high bar for safety.

Question 14

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.